-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gotistobart in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gotistobart in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gotistobart in Non-Small Cell Lung Cancer Drug Details: ONC-392...
-
Product Insights
Adenoid Cystic Carcinoma (ACC) – Drugs In Development, 2023
Global Markets Direct’s, ‘Adenoid Cystic Carcinoma (ACC) - Drugs In Development, 2023’, provides an overview of the Adenoid Cystic Carcinoma (ACC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adenoid Cystic Carcinoma (ACC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Anal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Anal Cancer - Drugs In Development, 2023’, provides an overview of the Anal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AI-061 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AI-061 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AI-061 in Solid Tumor Drug Details: AI-061 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Arsenic Trioxide in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Arsenic Trioxide in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Arsenic Trioxide in Mantle Cell Lymphoma Drug Details: Arsenic trioxide...